Differential miRNAs expression in papillary thyroid cancer is associated with clinico-pathological features and BRAF mutation

Castelblanco, Esmeralda; Rosado, Verónica; Martinez, Montserrat; Santos, María Dolores; Mancikova, Veronica; Robledo, Mercedes; Matías‐Guiu, Xavier; Maravall, Javier; Mauricio, Daniel

doi:10.1530/endoabs.35.p1095

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 12 studies were excluded, with reasons [79][80][81][82][83][84][85][86][87][88][89][90]. Specifically, two studies evaluated miRNA polymorphisms [89,90], and two studies reported data other than the prognostic role of miRNAs [79,87,88], which was not the topic of this review.…”

Section: Excluded Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The Prognostic Value of MicroRNAs in Thyroid Cancers—A Systematic Review and Meta-Analysis

Silaghi

Lozovanu

Silaghi

et al. 2020

Cancers

View full text Add to dashboard Cite

Thyroid cancer (TC) includes various phenotypes, from indolent to highly aggressive cancer. The limitations of the current prognostication systems to predict the recurrence risk and the variability in expression of the genes involved in the thyroid carcinogenesis uncover the need for new prognostic biomarkers by taking into account potential epigenetic differences. We aimed to summarize the current knowledge regarding the prognostic impact of microRNAs (miRNAs) in TC. A literature search was conducted in PubMed, Embase, Scopus, and Web of Science databases. Both upregulated and downregulated miRNAs are significantly correlated with worse overall survival (hazard ratio (HR) = 5.94, 95% CI: 2.73–12.90, p < 0.001; HR = 0.51, 95% CI: 0.26–0.96, p = 0.048) disease/recurrence-free survival (HR = 1.58, 95% CI: 1.08–2.32, p = 0.003; HR = 0.37, 95%, CI: 0.24–0.60, p < 0.001). Sensitivity analysis revealed a significant association between the higher expression of miR-146b, miR-221, and miR-222 and the recurrence of papillary TC (OR = 9.11, 95% CI 3.00 to 27.52; p < 0.001; OR = 3.88, 95% CI 1.34 to 11.19, p < 0.001; OR = 6.56, 95% CI 2.75 to 15.64, p < 0.001). This research identified that miR-146b, miR-221, and miR-222 could serve as potential prognostic biomarkers in TC, particularly in PTC. Further studies are needed to strengthen these findings and sustain its clinical applicability.

show abstract

Section: Excluded Studiesmentioning

confidence: 99%

“…The authors of one study extracted the patients' data from the TCGA database; for this reason, it was excluded [80]. For five studies, only a conference abstract was available, and no full-text article was published [81][82][83][84][85]; therefore, they were excluded.…”

Section: Excluded Studiesmentioning

confidence: 99%